Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. Issue 1 (2nd January 2019)

• Record Type: Journal Article
• Authors: Harth, Stefan; Ten Haaf, Andre; Loew, Christian; Frisch, Christian; Knappik, Achim
• Is Part Of: MAbs. Volume 11:Issue 1(2019)
• Page Start: 178
• Page End: 190
• Publication Date: 2019-01-02
• Subjects: Affinity maturation -- antibody phage display -- anti-drug antibody -- anti-idiotypic antibody -- guided selection -- ligand binding assays -- pharmacokinetic analysis -- therapeutic antibody; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2018.1538723
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Anti-idiotypic antibodies play an important role in pre-clinical and clinical development of therapeutic antibodies, where they are used for pharmacokinetic studies and for the development of immunogenicity assays. By using an antibody phage display library in combination with guided in vitro selection against various marketed drugs, we generated antibodies that recognize the drug only when bound to its target. We have named such specificities Type 3, to distinguish them from the anti-idiotypic antibodies that specifically detect free antibody drug or total drug. We describe the generation and characterization of such reagents for the development of ligand binding assays for drug quantification. We also show how these Type 3 antibodies can be used to develop very specific and sensitive assays that avoid the bridging format. Abbreviations: BAP: bacterial alkaline phosphatase; CDR: complementarity-determining regions in VH or VL; Fab: antigen-binding fragment of an antibody; HRP: horseradish peroxidase; HuCAL®: Human Combinatorial Antibody Libraries; IgG: immunoglobulin G; LBA: ligand binding assay; LOQ: limit of quantitation; NHS: normal human serum; PK: pharmacokinetics; VH: variable region of the heavy chain of an antibody; VL: variable region of the light chain of an antibody.